前列腺癌治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Prostate Cancer Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月10日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在全球前列腺癌盛行率上升的推动下，2024-2032年前列腺癌治疗市场规模将以8.8%的复合年增长率成长。根据《刺胳针》报道，摄护腺癌是 112 个国家男性中最常见的癌症，占所有癌症病例的 15%。随着对疾病早期检测和诊断的更广泛认识，需要能够解决从局部癌症到转移性癌症的各个阶段和形式的创新疗法。研发投资的增加，导致新药和治疗方式的推出，将促进市场成长。

人们越来越关注微创治疗方案。与传统手术方法相比，腹腔镜手术、机器人辅助手术以及高强度聚焦超音波 (HIFU) 和冷冻疗法等局部疗法可提供更短的恢復时间、更少的併发症以及更好地保存正常组织。医疗技术的进步、患者意识的提高以及对维持生活品质的治疗的日益偏好正在塑造市场前景。

前列腺癌治疗行业根据治疗、药物类别、给药途径、配销通路和地区进行分类。

到 2032 年，化疗领域将快速增长。包括新药物和治疗方案在内的下一代化疗药物的开发为先前治疗选择有限的转移性前列腺癌患者带来了新的希望。这些疗法根据患者的个别情况量身定制，从而製定更个人化和有效的治疗计划。

PARP 抑制剂部分将在 2032 年获得关注，因为它透过针对驱动癌症进展的特定途径彻底改变了前列腺癌的治疗。这些药物在癌症对传统荷尔蒙疗法产生抗药性的情况下特别有效。例如，恩杂鲁胺和醋酸阿比特龙等 ARI 已成为治疗去势抵抗性前列腺癌 (CRPC) 的主要药物，可提供显着的生存益处。同样，奥拉帕尼等 PARP 抑制剂的推出为治疗具有特定基因突变的患者开闢了新途径。

在发病率上升、意识增强和先进治疗方案采用的推动下，到 2032 年，欧洲前列腺癌治疗产业将出现可观的成长。该地区还受益于强大的医疗基础设施和有利的报销政策，有助于获得创新疗法。此外，欧洲领先的製药公司和研究机构的存在正在加速尖端治疗方法的开发和商业化，增加行业价值。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
Dendreon Pharmaceuticals LLC.
Exelixis, Inc
Ferring B.V.
GlaxoSmithKline Plc
Ipsen Pharma
Johnson and Johnson
Novartis AG
Pfizer Inc.
Sanofi S.A
Sumitomo Pharma America, Inc.
Takeda Pharmaceutical Company Limited
Tolmar Inc.

简介目录

Product Code: 10189

Prostate Cancer Therapeutics Market size will grow at an 8.8% CAGR during 2024-2032, driven by the rising prevalence of prostate cancer globally. According to The Lancet, prostate cancer is the most prevalent cancer among men in 112 countries, accounting for 15% of all cancer cases. With wider cognizance of early detection and diagnosis of the disease, there is a need for innovative therapies that can address various stages and forms of the disease, from localized to metastatic cancer. The heightened investment in R and D, leading to the introduction of new drugs and treatment modalities, will bolster the market growth.

There is an increasing focus on minimally invasive treatment options. Therapies, such as laparoscopic surgery, robotic-assisted surgery, and focal therapies like high-intensity focused ultrasound (HIFU) and cryotherapy, offer shorter recovery times, fewer complications, and better preservation of normal tissue compared to traditional surgical methods. The advancements in medical technology, greater patient awareness, and a growing preference for treatments that maintain quality of life are shaping the market outlook.

The prostate cancer therapeutics industry is classified based on therapy, drug class, route of administration, distribution channel, and region.

The chemotherapy segment will grow rapidly through 2032. New and improved chemotherapeutic agents, along with combination therapies, are enhancing patient outcomes by targeting cancer cells more effectively while minimizing side effects. The development of next-generation chemotherapies, including novel agents and regimens, is offering new hope to patients with metastatic prostate cancer, who previously had limited treatment options. These therapies are being tailored to individual patient profiles, leading to more personalized and effective treatment plans.

The PARP inhibitor segment will gain traction through 2032, as it has revolutionized prostate cancer treatment by targeting specific pathways that drive cancer progression. These drugs are particularly effective in cases where the cancer has become resistant to traditional hormone therapies. For instance, ARIs like enzalutamide and abiraterone acetate have become mainstays in treating castration-resistant prostate cancer (CRPC), providing significant survival benefits. Similarly, the introduction of PARP inhibitors such as Olaparib has opened new avenues for treating patients with specific genetic mutations.

Europe prostate cancer therapeutics industry will witness decent growth through 2032, driven by increasing incidence rates, growing awareness, and the adoption of advanced treatment options. The region is also benefiting from robust healthcare infrastructure and favorable reimbursement policies, which are facilitating access to innovative therapies. Moreover, the presence of leading pharmaceutical companies and research institutions in Europe is accelerating the development and commercialization of cutting-edge treatments, adding to industry value.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of prostate cancer
  - 3.2.1.2 Technological advancements
  - 3.2.1.3 Rising awareness and screening programs
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis
3.9 Future market trends
3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Hormonal therapy
5.3 Chemotherapy
5.4 Immunotherapy
5.5 Targeted therapy
5.6 Other therapies

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Androgen receptor inhibitors
6.3 GnRH receptor antagonist
6.4 PARP inhibitor
6.5 Immune checkpoint inhibitors
6.6 Other drug classes

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacy
8.3 Brick and mortar
8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa